Pharmacokinetics of Telbivudine in Healthy Subjects and Absence of Drug Interaction with Lamivudine or Adefovir Dipivoxil

@article{Zhou2006PharmacokineticsOT,
  title={Pharmacokinetics of Telbivudine in Healthy Subjects and Absence of Drug Interaction with Lamivudine or Adefovir Dipivoxil},
  author={Xiaojian Zhou and B. Fielman and D. Lloyd and G. Chao and N. Brown},
  journal={Antimicrobial Agents and Chemotherapy},
  year={2006},
  volume={50},
  pages={2309 - 2315}
}
  • Xiaojian Zhou, B. Fielman, +2 authors N. Brown
  • Published 2006
  • Medicine
  • Antimicrobial Agents and Chemotherapy
  • ABSTRACT Two phase I studies were conducted to assess the plasma pharmacokinetics of telbivudine and potential drug-drug interactions between telbivudine (200 or 600 mg/day) and lamivudine (100 mg/day) or adefovir dipivoxil (10 mg/day) in healthy subjects. Study drugs were administered orally. The pharmacokinetics of telbivudine were characterized by rapid absorption with biphasic disposition. The maximum concentrations in plasma (Cmax) were reached at median times ranging from 2.5 to 3.0 h… CONTINUE READING
    Pharmacokinetics of Telbivudine in Subjects with Various Degrees of Renal Impairment
    15
    Telbivudine: a review of its use in compensated chronic hepatitis B.
    14
    Safety and efficacy of telbivudine for the treatment of chronic hepatitis B
    10

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 32 REFERENCES
    Clinical Pharmacokinetics of Lamivudine
    235
    A dose‐finding study of once‐daily oral telbivudine in HBeAg‐positive patients with chronic hepatitis B virus infection
    105
    A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B.
    438
    Clinical Pharmacokinetics of the Antiviral Nucleotide Analogues Cidofovir and Adefovir
    264